tirzepatide hfpef trial Overview of key clinical trials and their cardiovascular In patients with cardiometabolic #HFpEF,

Tirzepatide (Mounjaro) dual GIP/GLP-1 receptor agonist) 3,4 3,4 Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist that produces superior weight loss compared with selective GLP-1 receptor agonists, through: Enhanced appetite suppression via dual receptor activation

L-Carnitine en melkzuur In lekentermen lijkt L-Carnitine zo krachtig in het verbeteren van de aerobe ademhaling op cellulair niveau dat het de eisen vermindert die aan het anaerobe systeem worden gesteld om ATP te produceren

Probiotic supplements or yoghurt containing live cultures have been suggested to help restore healthy oral and gut microbiota, though evidence for their effectiveness in treating halitosis is limited and inconsistent

: Speeds up recovery after intense workouts, promoting muscle repair, growth, and better mobility

Effects of GLP-1 receptor agonists on kidney and cardiovascular outcomes